Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795571 | 1.00 | KMT2A (0.46) | KMT2AMAPTSMN1; SMN2HTTADRB2 | |
| SCHEMBL6799219 | 0.93 | MAPT (0.48) | KMT2AMAPTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL6798687 | 0.93 | ALDH1A1 (0.45) | MAPTSMN1; SMN2ALDH1A1HPGDGAA | |
| SCHEMBL6800575 | 0.93 | ALDH1A1 (0.51) | KMT2AMAPTSMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL6798690 | 0.93 | ALDH1A1 (0.45) | MAPTSMN1; SMN2ALDH1A1HPGDGAA | |
| SCHEMBL6799222 | 0.93 | MAPT (0.48) | KMT2AMAPTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL6800578 | 0.93 | ALDH1A1 (0.51) | KMT2AMAPTSMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL6795630 | 0.92 | GAA (0.52) | MAPTSMN1; SMN2ALDH1A1HPGDGAA | |
| SCHEMBL6796997 | 0.92 | GAA (0.52) | MAPTSMN1; SMN2ALDH1A1HPGDGAA | |
| SCHEMBL6795635 | 0.92 | GAA (0.52) | MAPTSMN1; SMN2ALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762321-B2 | SUCH AS N-(2-(3,4-DIMETHOXYPHENYL)ETHYL)-3-DIFLUOROMETHOXY-2-(4 -METHYLPHENYL)ACRYLAMIDE; FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-07-13 | — | — | US | disclosed |
| US-20030195354-A1 | Amide compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1295868-A1 | AMIDE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195354-A1 | Amide compounds and use thereof | CBR1, CBR3, NAT1 | KMT2A 1480/4885MAPT 3676/4885SMN1; SMN2 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.